FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207612> ?p ?o ?g. }

• W4387207612 endingPage "S3" @default.
• W4387207612 startingPage "S2" @default.
• W4387207612 abstract "To evaluate the association between regular vaginal dilation and/or sexual activity and vaginal morbidity in locally advanced cervical cancer patients after definitive radiochemotherapy and image-guided adaptive brachytherapy from the EMBRACE I study.Physician-assessed vaginal morbidity (CTCAE v.3), vaginal dilation and patient-reported sexual activity (EORTC QLQ CX24) were assessed at baseline, every 3 months in the 1st year, every 6 months in the 2nd and 3rd year and yearly thereafter. For this longitudinal analysis, a subgroup of patients was selected with at least 3 follow-ups with information on vaginal dilation and/or sexual activity. Vaginal penetration summarized either the use of vaginal dilators or sexual activity or both. Regular vaginal penetration was defined if reported in ≥50%, infrequent if reported in <50% and absent if reported in 0% of follow-ups. Actuarial estimates of vaginal morbidity were calculated with Kaplan-Meier method and included the individual symptoms: vaginal dryness, stenosis, mucositis and bleeding. Group comparisons were evaluated with the log-rank test.The EMBRACE I study included 1416 patients overall (2008-2015); the subgroup of patients for this longitudinal evaluation consists of 882 patients, with a median follow-up of 60 months (IQR 47-77). Of those, 565 (64%) reported regular, 205 (23%) infrequent and 112 (13%) no penetration. Reporting regular penetration was associated with a significantly lower risk of vaginal stenosis G≥2 of 23% at 5 years, compared to reporting of infrequent (37%) and no penetration (36%, p≤0.001). However, reporting regular penetration was associated with a significantly higher risk for vaginal dryness G≥1 (72% vs. 69% vs. 62%, respectively, p = 0.038) and bleeding G≥1 (61% vs. 40% vs. 25%, respectively, p≤0.001). No associations were seen for G≥1 vaginal stenosis, G≥2 dryness, G≥2 bleeding and G≥1/G≥2 mucositis.Regular penetration (defined as vaginal dilation and/or sexual activity) was associated with lower risk for vaginal stenosis G≥2, but higher risk for vaginal dryness G≥1 and bleeding G≥1. Mild vaginal dryness seems to become apparent in particular for patients experiencing vaginal penetration. Minor vaginal blood loss during dilation and/or sexual activity is commonly reported by patients, resulting from atrophy of the vaginal mucosa and/or telangiectasia. While both of these G≥1 symptoms can be managed with lubricants, moisturizer and/or hormonal replacement therapy, G≥2 vaginal stenosis represents an irreversible fibrotic adverse event that can cause dyspareunia in many cancer patients. These long-term data support clinical recommendations for dilation and/or sexual activity after radiotherapy." @default.
• W4387207612 created "2023-09-30" @default.
• W4387207612 creator A5007180426 @default.
• W4387207612 creator A5008211705 @default.
• W4387207612 creator A5009197248 @default.
• W4387207612 creator A5010078716 @default.
• W4387207612 creator A5012456198 @default.
• W4387207612 creator A5018059259 @default.
• W4387207612 creator A5042729624 @default.
• W4387207612 creator A5051996971 @default.
• W4387207612 creator A5052993599 @default.
• W4387207612 creator A5053709216 @default.
• W4387207612 creator A5058848857 @default.
• W4387207612 creator A5065204901 @default.
• W4387207612 creator A5068282558 @default.
• W4387207612 creator A5071171991 @default.
• W4387207612 creator A5071659873 @default.
• W4387207612 creator A5072760427 @default.
• W4387207612 creator A5073239916 @default.
• W4387207612 creator A5077820862 @default.
• W4387207612 creator A5087566128 @default.
• W4387207612 creator A5091051978 @default.
• W4387207612 date "2023-10-01" @default.
• W4387207612 modified "2023-10-16" @default.
• W4387207612 title "Association between Regular Vaginal Dilation and/or Sexual Activity and Long-Term Vaginal Morbidity in Cervical Cancer Survivors" @default.
• W4387207612 doi "https://doi.org/10.1016/j.ijrobp.2023.06.207" @default.
• W4387207612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784450" @default.
• W4387207612 hasPublicationYear "2023" @default.
• W4387207612 type Work @default.
• W4387207612 citedByCount "0" @default.
• W4387207612 crossrefType "journal-article" @default.
• W4387207612 hasAuthorship W4387207612A5007180426 @default.
• W4387207612 hasAuthorship W4387207612A5008211705 @default.
• W4387207612 hasAuthorship W4387207612A5009197248 @default.
• W4387207612 hasAuthorship W4387207612A5010078716 @default.
• W4387207612 hasAuthorship W4387207612A5012456198 @default.
• W4387207612 hasAuthorship W4387207612A5018059259 @default.
• W4387207612 hasAuthorship W4387207612A5042729624 @default.
• W4387207612 hasAuthorship W4387207612A5051996971 @default.
• W4387207612 hasAuthorship W4387207612A5052993599 @default.
• W4387207612 hasAuthorship W4387207612A5053709216 @default.
• W4387207612 hasAuthorship W4387207612A5058848857 @default.
• W4387207612 hasAuthorship W4387207612A5065204901 @default.
• W4387207612 hasAuthorship W4387207612A5068282558 @default.
• W4387207612 hasAuthorship W4387207612A5071171991 @default.
• W4387207612 hasAuthorship W4387207612A5071659873 @default.
• W4387207612 hasAuthorship W4387207612A5072760427 @default.
• W4387207612 hasAuthorship W4387207612A5073239916 @default.
• W4387207612 hasAuthorship W4387207612A5077820862 @default.
• W4387207612 hasAuthorship W4387207612A5087566128 @default.
• W4387207612 hasAuthorship W4387207612A5091051978 @default.
• W4387207612 hasConcept C121608353 @default.
• W4387207612 hasConcept C126322002 @default.
• W4387207612 hasConcept C141071460 @default.
• W4387207612 hasConcept C2777416452 @default.
• W4387207612 hasConcept C2777744392 @default.
• W4387207612 hasConcept C2778220009 @default.
• W4387207612 hasConcept C2779076696 @default.
• W4387207612 hasConcept C2779234561 @default.
• W4387207612 hasConcept C2779755712 @default.
• W4387207612 hasConcept C2780218171 @default.
• W4387207612 hasConcept C2908647359 @default.
• W4387207612 hasConcept C29456083 @default.
• W4387207612 hasConcept C2986817661 @default.
• W4387207612 hasConcept C509974204 @default.
• W4387207612 hasConcept C54355233 @default.
• W4387207612 hasConcept C71924100 @default.
• W4387207612 hasConcept C86803240 @default.
• W4387207612 hasConcept C99454951 @default.
• W4387207612 hasConceptScore W4387207612C121608353 @default.
• W4387207612 hasConceptScore W4387207612C126322002 @default.
• W4387207612 hasConceptScore W4387207612C141071460 @default.
• W4387207612 hasConceptScore W4387207612C2777416452 @default.
• W4387207612 hasConceptScore W4387207612C2777744392 @default.
• W4387207612 hasConceptScore W4387207612C2778220009 @default.
• W4387207612 hasConceptScore W4387207612C2779076696 @default.
• W4387207612 hasConceptScore W4387207612C2779234561 @default.
• W4387207612 hasConceptScore W4387207612C2779755712 @default.
• W4387207612 hasConceptScore W4387207612C2780218171 @default.
• W4387207612 hasConceptScore W4387207612C2908647359 @default.
• W4387207612 hasConceptScore W4387207612C29456083 @default.
• W4387207612 hasConceptScore W4387207612C2986817661 @default.
• W4387207612 hasConceptScore W4387207612C509974204 @default.
• W4387207612 hasConceptScore W4387207612C54355233 @default.
• W4387207612 hasConceptScore W4387207612C71924100 @default.
• W4387207612 hasConceptScore W4387207612C86803240 @default.
• W4387207612 hasConceptScore W4387207612C99454951 @default.
• W4387207612 hasIssue "2" @default.
• W4387207612 hasLocation W43872076121 @default.
• W4387207612 hasLocation W43872076122 @default.
• W4387207612 hasOpenAccess W4387207612 @default.
• W4387207612 hasPrimaryLocation W43872076121 @default.
• W4387207612 hasRelatedWork W2003938723 @default.
• W4387207612 hasRelatedWork W2047967234 @default.
• W4387207612 hasRelatedWork W2118496982 @default.
• W4387207612 hasRelatedWork W2415160747 @default.
• W4387207612 hasRelatedWork W2439875401 @default.
• W4387207612 hasRelatedWork W4238867864 @default.

• next